Three of Celltrion's Leading Biosimilars Rank No. 1 in Prescriptions in Europe

Remsima Product Line Achieves 69% Market Share in Europe
Dominates Key Markets with 87% in the UK and 80% in Spain

Three of Celltrion's autoimmune disease and oncology biopharmaceuticals currently being sold have ranked first in prescriptions in Europe, a key global pharmaceutical market.

According to IQVIA, a pharmaceutical market research firm, as of the second quarter of this year, Celltrion's leading autoimmune disease treatment Remsima product line (IV and SC) has firmly maintained its top position in Europe with a 69% market share. Notably, it has recorded high prescription volumes in the major five European countries (EU5), including 87% in the United Kingdom and 80% in Spain. Even when looking at 'Remsima SC' (subcutaneous infliximab) alone, it has achieved significant results with a 34% market share in France and 29% in Germany. The five major European countries are Germany, the United Kingdom, France, Italy, and Spain.

Celltrion's autoimmune disease treatment drug Uplima. Celltrion

Another major autoimmune disease treatment from Celltrion, 'Uplima' (ingredient: adalimumab), has reached the top spot in prescriptions in Europe for the first time since its launch, with a 26% market share. Despite entering the market three years later than competitors in Europe, where being a 'First Mover' is advantageous, the product has achieved remarkable results thanks to its competitiveness and the direct sales capabilities of the local subsidiary.

Celltrion has also seen continued success in the oncology sector. 'Begzelma' (ingredient: bevacizumab), a treatment for metastatic colorectal cancer and breast cancer, has maintained the top prescription position in Europe with a 24% market share, supported by strong results in the United Kingdom (55%) and France (34%). In addition, 'Herzuma' (ingredient: trastuzumab) and 'Truxima' (ingredient: rituximab) have continued to lead with market shares of 32% and 30%, respectively, further solidifying Celltrion's reputation as a leading company in the field of oncology biosimilars.

These achievements are seen as the result of actual prescriptions following successful bids in major European countries such as Italy and Spain earlier this year, which have been reflected in the market data. Moreover, as Celltrion has strengthened its hospital and pharmacy network through direct sales, sales have expanded through retail distribution channels, leading to increased market share.

Building on the performance of its existing products, Celltrion plans to quickly secure a leading market position for newly launched follow-up products in the second half of this year. The number of countries selling 'Omiclou' (ingredient: omalizumab), a chronic spontaneous urticaria treatment launched as a first mover in Europe in September, is expanding. Additional new products, such as 'Eydengelth' (ingredient: aflibercept) for ophthalmic diseases and 'Stovoclo-Ocenbelt' (ingredient: denosumab) for bone diseases, are also scheduled for launch within the year. Celltrion intends to actively leverage the network established through existing product sales, as well as maximize marketing synergy based on portfolio expansion, to ensure early market penetration.

A Celltrion representative stated, "In the highly competitive biosimilar market, Celltrion's unique product competitiveness and direct sales capabilities have enabled our flagship products to achieve the number one prescription position in Europe, outperforming competitors. We will further strengthen our direct sales capabilities in Europe to ensure that the sales success of our existing products extends to newly launched products, and we will do our utmost to achieve both sales growth and improved profitability."